The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics

Malaria Journal

Volumn 6, Issue , 2007, Pages

  A Elbasit, Ishraga E ^a   Alifrangis, Michael ^b   Khalil, Insaf F ^b   Bygbjerg, Ib C ^b   Masuadi, Emad M ^c   Elbashir, Mustafa I ^a   Giha, Hayder A ^a,c  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; PYRIMETHAMINE; SULFADOXINE; ANTIMALARIAL AGENT; FANSIDAR; PROTOZOAL PROTEIN; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ARTICLE; CODON; CONTROLLED STUDY; DISEASE MARKER; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREQUENCY ANALYSIS; GAMETOGENESIS; GENE MUTATION; GENOTYPE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MUTANT; PARASITOSIS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; SUDAN; WILD TYPE; ANIMAL; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENE; GENE FREQUENCY; GENETICS; PARASITOLOGY; POINT MUTATION;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GENE FREQUENCY; GENES, PROTOZOAN; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; POINT MUTATION; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 36049010956     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-6-108     Document Type: Article

References (19)

1. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. J Le Bras R Durand, Fundam Clin Pharmacol 2003 17 147 153 10.1046/j.1472-8206.2003.00164.x 12667224
2. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. DS Peterson D Walliker TE Wellems, Proc Natl Acad Sci USA 1988 85 9114 9118 2904149 10.1073/pnas.85.23.9114
3. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. T Triglia JG Menting C Wilson AF Cowman, Proc Natl Acad Sci USA 1997 94 13944 13949 9391132 10.1073/pnas.94.25.13944
4. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. IM Hastings MJ Donnelly, Drug Resist Updat 2005 8 43 50 10.1016/j.drup.2005.03.003 15939341
5. Fitness of drug-resistant malaria parasites. D Walliker P Hunt H Babiker, Acta Trop 2005 94 251 259 15845348
6. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. KI Barnes NJ White, Acta Trop 2005 94 230 240 15878154
7. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. D Francis SL Nsobya A Talisuna A Yeka MR Kamya R Machekano C Dokomajilar PJ Rosenthal G Dorsey, J Infect Dis 2006 193 978 986 10.1086/500951 16518760
8. Monitoring antimalarial drug resistance: making the most of the tools at hand. CV Plowe, J Exp Biol 2003 206 3745 3752 10.1242/jeb.00658 14506209
9. The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis. IE A-Elbasit MI Elbashir IF Khalil M Alifrangis HA Giha, Trop Med Int Health 2006 11 604 612 10.1111/j.1365-3156.2006.01616.x 16640612
10. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated malaria in areas with intense transmission. WHO, WHO, Geneva 1996 (WHO/MAL/96.1077)
11. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. RJ Pearce C Drakeley D Chandramohan F Mosha C Roper, Antimicrob Agents Chemother 2003 47 1347 1354 12654669 10.1128/AAC.47.4.1347-1354.2003
12. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistence genes using polymerase chain reaction and enzyme-linked immunosorbent assay-based technology. M Alifrangis S Enosse R Pearce C Drakeley C Roper IF Khalil WM Nkya AM Ronn TG Theander IC Bygbjerg, Am J Trop Med Hyg 2005 72 155 162 15741552
13. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. AA Djimde OK Doumbo O Traore AB Guindo K Kayentao Y Diourte S Niare-Doumbo D Coulibaly AK Kone Y Cissoko M Tekete B Fofana A Dicko DA Diallo TE Wellems D Kwiatkowski CV Plowe, Am J Trop Med Hyg 2003 69 558 563 14695097
14. A molecular marker for chloroquine-resistant falciparum malaria. A Djimde OK Doumbo JF Cortese K Kayentao S Doumbo Y Diourte A Dicko XZ Su T Nomura DA Fidock TE Wellems CV Plowe D Coulibaly, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152
15. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt /pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum. ME Osman FP Mockenhaupt U Bienzle MI Elbashir H Giha, Infect Genet Evol 2007 7 52 59 10.1016/j.meegid.2006.03.008 16690361
16. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. JT Bousema LC Gouagna AM Meutstege BE Okech NI Akim JI Githure JC Beier RW Sauerwein, Trop Med Int Health 2003 8 427 430 10.1046/j.1365-3156.2003.01047.x 12753638
17. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. L von Seidlein M Jawara R Coleman T Doherty G Walraven G Targett, Trop Med Int Health 2001 6 92 98 10.1046/j.1365-3156.2001.00683.x 11251903
18. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. F Mendez A Munoz G Carrasquilla D Jurado M Arevalo-Herrera JF Cortese CV Plowe, Am J Epidemiol 2002 156 230 238 10.1093/aje/kwf030 12142257
19. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. FP Mockenhaupt J Teun Bousema TA Eggelte J Schreiber S Ehrhardt N Wassilew RN Otchwemah RW Sauerwein U Bienzle, Trop Med Int Health 2005 10 901 908 10.1111/j.1365-3156.2005.01471.x 16135198